Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04090775 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma
A Phase 2 study, sponsored by Rampart Health, L.L.C..
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04090775: Completed Phase 2 study, sponsored by Rampart Health, L.L.C..
NCT04090775 is a Phase 2 study that has completed, run by Rampart Health, L.L.C.. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04090775, a Phase 2 study, has completed, sponsored by Rampart Health, L.L.C..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study seeks to estimate the occurrence of adverse events related to the study treatment (Cryosurgical freezing and Intratumoral Combination Immunotherapy), as well as determine the potential efficacy.
Primary Outcome
Primary Endpoint: Efficacy of cryosurgical freezing and intratumoral combination immunotherapy as determined by the proportion of patients achieving serum PSA decline from baseline of at least 50%.
Interventions
- DRUG Cytoxan
- DRUG Yervoy Injectable Product
- PROCEDURE Cryosurgical freezing (cryosurgery)
- DRUG Opdivo Injectable Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-06-28 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 2 |
What the finished NCT04090775 record still lists
NCT04090775 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 4 interventions - of which Cytoxan is the first listed.
NCT04090775 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04090775 about?
NCT04090775 is a clinical study titled "A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma". This study seeks to estimate the occurrence of adverse events related to the study treatment (Cryosurgical freezing and Intratumoral Combination Immunotherapy), as well as determine the potential efficacy.
What is the current status of trial NCT04090775?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2019-06-28. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT04090775?
The interventions under investigation include: Cytoxan (DRUG), Yervoy Injectable Product (DRUG), Cryosurgical freezing (cryosurgery) (PROCEDURE), Opdivo Injectable Product (DRUG).
Who is sponsoring clinical trial NCT04090775?
This trial is sponsored by Rampart Health, L.L.C., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04090775's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI